Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | EV-103 Cohort K: enfortumab vedotin +/- pembro in untreated cis-ineligible patients with mUC

Tolerable first-line treatment options in metastatic urothelial carcinoma (mUC) represent an unmet clinical need. In this interview, Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of Cohort K of the EV-103 study (NCT03288545) which aimed to evaluate the antitumor activity of enfortumab vedotin monotherapy or in combination with pembrolizumab in previously untreated cisplatin-ineligible patients with locally advanced or mUC. Enfortumab vedotin plus pembrolizumab showed high overall response rates with rapid responses. Median duration of response was not reached in this patient population. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.